论文部分内容阅读
目的:检测高分子量细胞角蛋白(34βE12)和上皮钙粘蛋白(E-cadherin)在甲状腺乳头状癌(PTC)组织中的表达,筛选甲状腺乳头状癌的辅助诊断指标及预测淋巴结转移的可能性。方法:采用免疫组化S-P法,DAB显色检测结节性甲状腺肿伴乳头状增生15例,甲状腺乳头状癌32例(无淋巴结转移22例,有淋巴结转移10例)中34βE12、E-cadherin的表达。结果:(1)34βE12表达以甲状腺乳头状癌有淋巴结转移最强(100%),无淋巴结转移较低(81.8%),甲状腺乳头状增生更低(26.7%),3组有显著差异(P<0.01)。(2)E-Cadherin表达以甲状腺乳头状增生最强(100%),甲状腺乳头状癌无淋巴结转移较低(36.4%),有淋巴结转移更低(10%),3组间有显著差异(P<0.01)。(3)根据两种蛋白表达阳性率行统计学分析,结果显示两种蛋白表达强度相互之间无相关性。结论:(1)甲状腺乳头状癌组织中34βE12表达率增高,而E-cadherin表达率低。(2)E-cadherin、34βE12对于甲状腺乳头状癌的诊断具有一定的指导作用。(3)E-cadherin有望作为预测淋巴结转移的参考指标。
OBJECTIVE: To detect the expression of high molecular weight cytokeratin (34βE12) and E-cadherin in thyroid papillary carcinoma (PTC) and to screen the diagnostic indexes of papillary thyroid carcinoma and predict the possibility of lymph node metastasis . Methods: The expressions of 34βE12 and E-cadherin in 15 cases of nodular goiter with papillary hyperplasia, 32 cases of papillary thyroid carcinoma (22 cases without lymph node metastasis and 10 cases with lymph node metastasis) were detected by immunohistochemical SP method and DAB colorimetry. expression. Results: (1) The expression of 34βE12 in thyroid papillary carcinoma was the strongest (100%) with no lymph node metastasis (81.8%), the papillary hyperplasia was lower (26.7%), the difference was significant among the three groups (P <0.01). (2) E-Cadherin expression was the strongest in thyroid papillary hyperplasia (100%), thyroid papillary carcinoma with no lymph node metastasis was lower (36.4%), lymph node metastasis was lower (10%), there was significant difference among the three groups P <0.01). (3) According to the statistical analysis of the positive rates of the two proteins, the results showed that the expression intensity of the two proteins had no correlation with each other. Conclusions: (1) The expression of 34βE12 in thyroid papillary carcinoma is increased, while the expression of E-cadherin is low. (2) E-cadherin, 34βE12 has some guidance for the diagnosis of papillary thyroid carcinoma. (3) E-cadherin is expected as a reference index for predicting lymph node metastasis.